Vallery Ogello
Overview
Explore the profile of Vallery Ogello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
25
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okello P, Ogello V, Thuo N, Gakuo S, Mwangi P, Mogere P, et al.
Pan Afr Med J
. 2025 Jan;
49:31.
PMID: 39886110
No abstract available.
2.
Ogello V, Mwangi P, Kwena Z, Thuo N, Makokha C, Owidi E, et al.
BMC Infect Dis
. 2025 Jan;
25(1):37.
PMID: 39773105
Background: Increased risk of HIV acquisition during pregnancy and lactation among women is evident, necessitating their inclusion in the evaluation of new HIV prevention interventions. Pregnant and postpartum women specifically...
3.
Okello P, Velloza J, Ogello V, Owidi E, Mogere P, Gakuo S, et al.
AIDS Care
. 2024 Dec;
37(2):324-336.
PMID: 39733245
Objective measures of oral PrEP adherence - especially point-of-care (POC) measures that enable real-time assessment, intervention, and feedback - have the potential to improve adherence. Our team previously developed and...
4.
Ogello V, Ngure K, Mwangi P, Owidi E, Wairimu N, Etyang L, et al.
J Int Assoc Provid AIDS Care
. 2024 Aug;
23:23259582241274311.
PMID: 39155573
HIV self-testing (HIVST) has the potential to reduce barriers associated with clinic-based preexposure prophylaxis (PrEP) delivery. We conducted a substudy nested in a prospective, pilot implementation study evaluating patient-centered differentiated...
5.
Gandhi M, Glidden D, Chakravarty D, Wang G, Biwott C, Mogere P, et al.
Lancet HIV
. 2024 Jul;
11(8):e522-e530.
PMID: 38976993
Background: Adherence challenges with oral tenofovir-based pre-exposure prophylaxis (PrEP) are common. We developed a point-of-care assay to objectively assess tenofovir in urine and conducted a pilot trial examining the impact...
6.
Ogello V, Thuo N, Okello P, Wairimu N, Mwangi P, Maina G, et al.
Behav Sci (Basel)
. 2024 May;
14(5).
PMID: 38785842
Background: In 2020, healthcare providers were expected to provide care to individuals with coronavirus disease 2019 (COVID-19), putting them at risk of acquiring COVID-19. The possibility of acquiring poorly understood...
7.
Zewdie K, Ngure K, Mwangi M, Mwangi D, Maina S, Etyang L, et al.
J Int AIDS Soc
. 2024 Mar;
27(3):e26222.
PMID: 38446643
Introduction: Delivery of oral pre-exposure prophylaxis (PrEP) is being scaled up in Africa, but clinic-level barriers including lengthy clinic visits may threaten client continuation on PrEP. Methods: Between January 2020...
8.
Ngure K, Thuo N, Ogello V, Kiptinness C, Kamolloh K, Burns B, et al.
Front Reprod Health
. 2022 Oct;
3:637869.
PMID: 36304002
In Kenya and elsewhere in sub-Saharan Africa, young women are disproportionately affected by the HIV epidemic compared to young men. The extent to which young women's self-perceptions about risk of...
9.
Katz I, Ngure K, Kamolloh K, Ogello V, Okombo M, Thuo N, et al.
AIDS Behav
. 2022 Aug;
27(1):106-118.
PMID: 35930203
Few studies have focused on understanding pre-exposure prophylaxis (PrEP) non-initiation among young, high-risk women in sub-Saharan Africa. This study aimed to qualitatively explore why young women in Kenya at high-risk...
10.
Ogello V, Ngure K, Thuo N, Burns B, Rono B, Oware K, et al.
AIDS Behav
. 2022 Jul;
27(1):65-74.
PMID: 35907142
Adherence to oral pre-exposure prophylaxis (PrEP) is challenging, and cellular technology offers a promising opportunity for support. However, a recent randomized controlled trial found that SMS reminders did not improve...